Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals’ patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company’s founder.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
DibbsBarker is closing its doors after signing a deal that will see 17 partners and support staff move to Dentons, the world’s largest firm.
Global law firm Dentons has expanded its presence in Australia with a fifth office Down Under, this one in Melbourne.
Lawyers are advising large companies to look hard at their business plans to keep on the good side of the Australian Competition and Consumer Commission now that the enforcer has a new arsenal to deploy.